Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab vs Secukinumab in Plaque Psoriasis (OASIS-2)
NCT03535194Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of mirikizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Jun 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03535194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03535194.